Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Decrease in Short Interest

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) was the target of a significant drop in short interest in December. As of December 15th, there was short interest totaling 2,994,328 shares, a drop of 21.3% from the November 30th total of 3,806,493 shares. Approximately 5.9% of the company’s stock are sold short. Based on an average trading volume of 3,866,199 shares, the days-to-cover ratio is currently 0.8 days. Based on an average trading volume of 3,866,199 shares, the days-to-cover ratio is currently 0.8 days. Approximately 5.9% of the company’s stock are sold short.

Insider Activity

In related news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the transaction, the insider directly owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. This trade represents a 40.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert J. Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $11.03, for a total transaction of $165,450.00. Following the completion of the sale, the director owned 484,864 shares of the company’s stock, valued at $5,348,049.92. This trade represents a 3.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.00% of the stock is currently owned by company insiders.

Institutional Trading of Fulcrum Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. increased its holdings in Fulcrum Therapeutics by 186.1% in the first quarter. Invesco Ltd. now owns 85,767 shares of the company’s stock valued at $247,000 after buying an additional 55,791 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Fulcrum Therapeutics during the 1st quarter valued at about $441,000. American Century Companies Inc. grew its position in shares of Fulcrum Therapeutics by 2.6% during the 1st quarter. American Century Companies Inc. now owns 123,711 shares of the company’s stock valued at $356,000 after acquiring an additional 3,100 shares during the period. Jump Financial LLC purchased a new position in shares of Fulcrum Therapeutics in the 1st quarter valued at about $30,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Fulcrum Therapeutics in the 1st quarter worth about $164,000. 89.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on FULC shares. Bank of America raised their price target on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a report on Tuesday, December 9th. Royal Bank Of Canada raised their target price on Fulcrum Therapeutics from $7.00 to $10.00 and gave the stock a “sector perform” rating in a research note on Monday, December 8th. Wall Street Zen upgraded Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Truist Financial increased their price objective on Fulcrum Therapeutics from $14.00 to $18.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $23.00 target price (up previously from $16.00) on shares of Fulcrum Therapeutics in a report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.00.

Fulcrum Therapeutics Stock Performance

Fulcrum Therapeutics stock traded down $0.65 during midday trading on Tuesday, hitting $11.34. 858,743 shares of the company were exchanged, compared to its average volume of 754,715. The firm has a market capitalization of $613.72 million, a PE ratio of -9.61 and a beta of 3.17. Fulcrum Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $15.74. The business has a fifty day simple moving average of $10.44 and a two-hundred day simple moving average of $8.53.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). As a group, equities analysts expect that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.